This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mosqueira, V. C. F.
Right arrow Articles by Barratt, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mosqueira, V. C. F.
Right arrow Articles by Barratt, G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2004, p. 1222-1228, Vol. 48, No. 4
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.4.1222-1228.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Efficacy and Pharmacokinetics of Intravenous Nanocapsule Formulations of Halofantrine in Plasmodium berghei-Infected Mice

Vanessa C. F. Mosqueira,1,2 Philippe M. Loiseau,3 Christian Bories,3 Philippe Legrand,1 Jean-Philippe Devissaguet,1 and Gillian Barratt1*

UMR CNRS 8612,1 BIOCIS, UPRES A CNRS 8076, Faculté de Pharmacie, Université de Paris-Sud, 92296 ChÂtenay Malabry, France,3 DEFAR, Escola de Farmácia, Universidade Federal de Ouro Preto, 35400000 MG, Brazil2

Received 25 March 2003/ Returned for modification 6 September 2003/ Accepted 6 January 2004

The efficacy and pharmacokinetics of a new parenteral formulation of halofantrine were studied in mice infected with Plasmodium berghei. The formulation consisted of nanocapsules with an oily core, prepared from either poly(D,L-lactide) (PLA) homopolymer or PLA that was surface modified with grafted polyethylene glycol chains. They were compared with a previously described intravenous halofantrine preparation. No toxic effects were observed with halofantrine in form of nanocapsules after intravenous administration for doses of up to 100 mg/kg, whereas the solubilized form in polyethylene glycol-dimethylacetamide was toxic at this dose. The halofantrine-loaded nanocapsules showed activity that was similar to or better than that of the solution in the 4-day test and as a single dose in severely infected mice, with only minimal differences between the two nanocapsule formulations. Halofantrine pharmacokinetics were determined in parallel with parasite development in severely infected mice. Nanocapsules increased the area under the curve for halofantrine in plasma more than sixfold compared with the solution throughout the experimental period of 70 h. Furthermore, nanocapsules induced a significantly faster control of parasite development than the solution in the first 48 h posttreatment. While the parasitemia fell more rapidly with PLA nanocapsules, the effect was more sustained with the surface-modified ones. This is consistent with surface-modified nanocapsules remaining longer in the circulation. These results suggest that nanocapsule formulations could provide a more favorable halofantrine profile in the plasma and reduce the intravenous dose necessary and therefore the toxicity, thus suggesting the use of halofantrine by a parenteral route in severe malaria.

* Corresponding author. Mailing address: UMR CNRS 8612, Faculté de Pharmacie, Université de Paris-Sud, 92296 ChÂtenay Malabry, France. Phone: 33 1 46 83 56 27. Fax: 33 1 46 61 93 34. E-mail: Gillian.Barratt{at}cep.u-psud.fr.

Antimicrobial Agents and Chemotherapy, April 2004, p. 1222-1228, Vol. 48, No. 4
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.4.1222-1228.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»